Table 3

Clinical Follow-Up

Sildenafil Group (n = 50)PADN Group (n = 48)p Value
Diuretics dosage (total), mg/day
 Before enrollment40 (0 to 90)40 (0 to 80)0.754
 At 6 months60 (20 to 155)24 (0 to 140)0.030
  Titration24 (48.0)6 (12.5)0.031
Target drugs
 Monotherapy (sildenafil)50 (100.0)0 (0.0)NS
 Combined with prostacyclin analog1 (2.0)0 (0.0)NS
 Calcium channel blocker26 (52.0)20 (41.7)0.604
 Endothelin receptor antagonist0 (0.0)0 (0.0)NS
NT-proBNP, pg/ml
 Before PADN1,345 (145 to 14,293)1,601 (104 to 13,876)0.803
 At 6 months1,345 (31 to ∼9,563)809 (25 to ∼5,004)0.001
 Net reduction, %−6.2 (−82 to ∼54)−47.5 (−99 to ∼33.1)0.003
NYHA functional class, at 6 months2.51 ± 0.752.13 ± 0.570.012
 n4546
 Class I0 (0.0)10 (20.0)
 Class II28 (63.6)25 (54.3)
 Class III/IV16 (36.4)11 (23.9)
Borg index, score1.19 ± 0.661.09 ± 0.580.548
Clinical worsening20 (40.0)8 (16.7)0.014
 All-cause death5 (10.0)2 (4.2)0.436
 Rehospitalization14 (28.0)6 (12.5)0.052
 Worsening of heart failure18 (36.0)7 (14.6)0.016
 Heart transplantation1 (2.0)0 (0.0)NS

Values are median (interquartile range), n (%), n, or mean ± SD.

NT-proBNP = N-terminal pro–B-type natriuretic peptide; other abbreviations as in Table 1.

  • Used in 1 patient at 162 days after randomization.